Summary Adrenal androgens show a dual and apparently opposite effect on the growth of oestrogenresponsive breast cancer: they stimulate growth on their own, but counteract the growth-stimulatory effect of oestrogens. Focusing on the inhibitory action we have studied the effects of 5-en-androstene-3p,17p-diol (ADIOL) on the growth of oestrogen-responsive MCF-7 breast cancer cells in the presence of oestrogens (oestradiol and diethylstilboestrol), antiestrogens (tamoxifen) and antiandrogens (hydroxyflutamide). The inhibition of oestrogen-stimulated growth, attained with nanomolar concentrations of ADIOL, was not modified by increasing concentrations of diethylstilboestrol up to 100 nm. This inhibition was counteracted by antiandrogens, which were unable to block the ADIOL stimulatory effect in steroid-free medium. On the other hand, in the presence of tamoxifen ADIOL showed an additive antiproliferative activity also in steroid-free medium, rather than the usual stimulatory effect. These results suggest that ADIOL stimulates breast cancer cell growth via oestrogen receptors, but inhibits oestrogen-stimulated growth via androgen receptors.
products of the adrenal gland. However, their physiological role is still unknown. Epidemiological and experimental studies suggest that they might affect the growth of human breast tumours (Bulbrook et al., 1971; Wang et al., 1975; Segaloff et al., 1980; Zumoff et al., 1981; Helzlsouer et al., 1992) . In vitro studies showed that they may exert a dual and opposite effect on the growth of breast cancer cells (Adams et al., 1981; Poulin & Labrie, 1986; Najid & Habrioux, 1990; Boccuzzi et al., 1992a) . ADIOL is able to stimulate the in vitro growth of oestrogen-dependent breast cancer cell lines in steroid-free medium when added at the concentrations found in the plasma of post-menopausal women (Nahoul et al., 1985) . Moreover, it is coupled with the transcriptional activation of proteins which are markers of oestrogenic action (Adams et al., 1981; Poulin & Labrie, 1986) . The growth-stimulatory activity of ADIOL depends on its direct binding to oestrogen receptors (ERs) Kreitman & Bayard, 1979; Adams et al., 1980; Rochefort & Garcia, 1984) , without any involvement of the aromatase pathway (Najid, 1991; Pizzini et al., 1992) . On the other hand, we have recently shown that ADIOL inhibits the oestradiol-induced growth of human breast cancer cells (Boccuzzi et al., 1992a) . The mechanism of this antiproliferative action has not yet been clarified. As ADIOL binds to ERs, it might partially displace oestradiol (E2) from its own receptors (Thjissen et al., 1975; Garcia & Rochefort, 1978; Nicholson et al., 1978) . Alternatively, since ADIOL binds also androgen receptors (ARs) and exerts full androgenic activity (Rosenfield & Otto, 1972; Demish et al., 1973; Hackemberg et al., 1993) , it might inhibit growth via ARs.
To clarify the mechanisms of the ADIOL antiproliferative action, i.e. to differentiate between an ER-and AR-mediated activity, we evaluated its effects on the growth of the hormone-responsive MCF-7 breast cancer cells in presence of the antioestrogen tamoxifen (TAM), of the antiandrogen hydroxyflutamide (OH-FLU) and of the non-steroidal oestrogen diethylstilboestrol (DES). Data indicate that AR activation is involved in the antiproliferative action of ADIOL. This offers an experimental background for the suggestion that a combined hormonal therapy approach might be superior to TAM alone in the post-menopausal breast cancer.
Materials and methods
Chemicals ADIOL, E2, dihydrotestosterone (DHT), TAM and DES were purchased from Sigma (USA). OH-FLU was from Schering Plough (USA). The compounds were diluted in ethanol; the final concentration of ethanol in the medium did not exceed 0.1%, which had no detectable effect on cell growth. However, ethanol at the same concentration was also added to the medium of control cultures. Fetal calf serum (FCS) (Eurobio, France) was treated with charcoal dextran (10:1) to remove steroids; the extraction was carried out at 25°C for 60 min.
Cell culture
The MCF-7 cell line was from the American Type Culture Collection (USA). Cells were cultured in 25 cm2 plastic flasks (Falcon, USA) in RPMI-1640 phenol red-free medium (Gibco, UK), supplemented with 2mM L-glutamine (Eurobio, France), 100 IU ml-' penicillin G, 100 fig ml-' streptomycin and with 10% FCS added. The cells were grown in a humidified atmosphere containing 5% (v/v) carbon dioxide at 37'C. The medium was changed every 2 days. The cells were passaged weekly by trypsin 0.05% and EDTA 0.02%.
Cell proliferation experiments in culture
Approximately 2 x 104 cells per well were plated in 24-well culture plates (Falcon, USA). Cells were allowed to attach for 24 h in the medium supplemented with 10% steroidstripped FCS. Then the seeding medium was replaced with one containing hormones (for details about media see the figure legends). The medium was renewed on the fourth day. Cells were harvested by trypsin at the established time and counted (twice for each well) using a Burker chamber. Statistical evaluation was carried out on paired data using Student's t-test. while a very high DHT concentration (200 nM) stimulates MCF-7 cell growth through an oestrogen receptor-mediated mechanism (Zava & McGuire, 1978) . The administration of ADIOL (0.2-200 nM) together with E2 ( Figure 3 ) inhibits E2-induced cell proliferation: cell number per plate at day 6 of culture is lower (P<0.001) than after stimulation by E2 alone (Figure 1 ). The inhibitory effect of 2 nM ADIOL on cell proliferation is maintained in increasing E2 concentrations up to 10 nM (Figure 3 ). The administration of DHT (0.2-200 nM) together with 1 nM E2 has an inhibitory effect similar to that of ADIOL (Figure 3 ). Growth curves of E2 alone, E2 plus ADIOL and E2 plus DHT are presented in Figure 4 . At 2 x 10-4 cells cm-2 well seeding density, both ADIOL and DHT affect log phase growth. Figure 1 ). In preliminary experiments we observed that, in 10% FCS steroid-stripped culture medium, 1 gM TAM completely counteracts the stimulatory effect of 1 nM E2 on cell growth ( Table I ).
Results

Effect
Effect of ADIOL on MCF-7 cell growth in the presence of diethylstilboestrol (DES) DES stimulation of MCF-7 cell growth is shown in Figure 5 . ADIOL at 2 nM was added together with DES at concentrations of up to 100 nM. As expected, at DES concentrations unable to influence cell proliferation, ADIOL induces a maximal 2-fold stimulation of cell proliferation, acting as oestrogen. Conversely, the inhibitory effect of ADIOL becomes evident at higher DES concentrations: the cell number at day 6 of culture is lower in the presence of DES + ADIOL than in the presence of DES alone. The effect is maintained at maximally stimulating DES concentrations.
Effect of hydroxyflutamide (OH-FLU) on MCF-7 cell growth
The effects on cell growth of the antiandrogen OH-FLU, which binds to ARs with a much greater affinity than flutamide (Neri et al., 1972; Simard et al., 1986; Brogden & Chrisp, 1991) , are shown in Figure 6 . The dose-response curve shows that OH-FLU completely reverses the inhibitory effect of ADIOL on E2-induced cell growth, suggesting that this effect is mediated by AR. Figure 6 also shows that OH-FLU at high concentration, alone or in combination with either E2 or ADIOL, exerts a negligible antiproliferative effect. This effect of OH-FLU on breast cancer cell growth has been reported previously (Di Monaco et al., 1993) .
Discussion
We have previously reported that adrenal androgens are able to decrease the growth of dimethylbenz[a]anthracene (DMBA)-induced mammary tumours in adult rats (Boccuzzi et al., 1992b) as well as to inhibit in vitro the oestrogendependent proliferation of MCF-7 breast cancer cells (Boccuzzi et al., 1992a) . In this paper the mechanism of the antiproliferative action of ADIOL on the oestradiol-induced growth of breast cancer cells was investigated. ADIOL binding to ERs Kreitman & Bayard, 1979; Adams et al., 1980) has been suggested to account for its antioestrogenic action: it might displace E2 from ERs, antagonising the stronger E2 stimulatory activity (Thjissen et al., 1975; Garcia & Rochefort, 1978; Nicholson et al., 1978 OH-FLU (log M) Figure 6 Effect of increasing concentrations of hydroxyflutamide on the cell growth. Cells were seeded at a density of about 2 x 1O4cells per dish and cultured in a medium supplemented with 10% steroid-stripped fetal calf serum. One day after seeding, OH-FLU was added to cell cultures at the indicated concentrations in the absence (0, control) inhibition is mediated by ARs, being specifically counteracted by antiandrogens (Maclndoe & Etre, 1981; Poulin et al., 1988 Poulin et al., , 1989 (Bulbrook et al., 1971; Wang et al., 1975; Segaloff et al., 1980; Zumoff et al., 1981; Helzlsouer et al., 1992) and are supported by experimental data showing that adrenal androgens can exert opposite effects on rat mammary tumours, depending on the oestrogenic environment (Boccuzzi et al., 1992b) . It should also be emphasised that the inhibitory effect of ADIOL is maintained in the presence of TAM. A similar additive inhibitory action, via AR activation, has already been shown for DHT (Poulin et al., 1988) and for fluoxymesterone (Ingle et al., 1991) . Although a large body of experimental as well as clinical data shows that the antitumour activity of TAM is due to ER-mediated blockade of oestrogen action, TAM also displays several additional properties, independent of ERs, which are important in the control of cellular proliferation (Huynh et al., 1993) . Our data suggest that antioestrogens might influence breast cancer growth by an additional and indirect pathway: ER blockade by tamoxifen might allow ADIOL and other androgens from the adrenals and ovaries to exert antiproliferative effects via ARs. The additive effect shown in vitro by ADIOL and TAM may have clinical relevance. Aromatase inhibitors such as 4-hydroxyandrostendione, which reduces the conversion of adrenal androgens to oestradiol, are presently recommended as an alternative to tamoxifen in breast cancer therapy. Evidence of an additive effect of adrenal androgen and antioestrogens might suggest the simultaneous administration of aromatase inhibitors and tamoxifen: aromatase inhibitors could block the conversion of adrenal androgens, allowing their direct inhibition of cell proliferation. The inhibition mediated by AR could be obtained only if ERs are simultaneously blocked by antioestrogens.
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